NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 56 resultados LastUpdate Última actualización 26/04/2018 [15:35:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


MONOCLONAL ANTI-GT468 ANTIBODIES FOR TREATMENT OF CANCER

NºPublicación: EP3312198A1 25/04/2018

Solicitante:
GANYMED PHARMACEUTICALS GMBH [DE]
JOHANNES GUTENBERG UNIV MAINZ [DE]

Resumen de: EP3312198A1

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.



traducir


 

ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA

NºPublicación: EP3312196A1 25/04/2018

Solicitante:
GENMAB AS [DK]

Resumen de: EP3312196A1

Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.



traducir


 

DEUTERIUM-SUBSTITUTED DEHYDROPHENYLAHISTIN-LIKE COMPOUND, PREPARATION METHOD THEREOF AND USE IN PREPARATION OF ANTITUMOR DRUG

NºPublicación: EP3312163A1 25/04/2018

Solicitante:
MARINE BIOMEDICAL RES INSTITUTE OF QINGDAO CO LTD [CN]

Resumen de: EP3312163A1

Provided are a deuterium-substituted dehydrophenylahistin-like compound, preparation method thereof and use in a preparation of antitumor drugs. The deuterium-substituted dehydrophenylahistin-like compound has a structure of general formula (I), and a synthesis method thereof comprises: firstly conducting a condensation reaction of diacetyldiketopiperazine and an aldehyde intermediate a or a deuterated aldehyde compound b to form a heterocyclic compound c or a deuterium-containing heterocyclic compound d, which is then subjected to a condensation reaction with benzaldehyde and a deuterium-substituted benzaldehyde-like compound to form the deuterium-substituted dehydrophenylahistin-like compound. Also provided are a highly effective deuterated aldehyde intermediate with a high deuterium substitution rate and a deuterium-containing heterocycle intermediate, and a synthesis method thereof. An experiment shows that the deuterium-substituted dehyd- rophenylahistin-like compound provided by the present invention has an effect on tubulin depolymerization and can treat a refractory solid tumor or lymphoma. The present invention provides a method for researching and developing antitumor drugs of the related compound.



traducir


 

COMBINATION THERAPY USING BELINOSTAT AND PRALATREXATE TO TREAT LYMPHOMA

NºPublicación: EP3310350A1 25/04/2018

Solicitante:
SPECTRUM PHARMACEUTICALS INC [US]

Resumen de: WO2016205203A1

The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.



traducir


 

4-(2-AMINO-TETRAHYDRONAPHTHALENYL)PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING SAME AS ACTIVE INGREDIENT

NºPublicación: US2018104242A1 19/04/2018

Solicitante:
KOREA RES INST CHEMICAL TECH [KR]

Resumen de: US2018104242A1

The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.



traducir


 

METHODS AND COMPOSITIONS FOR INHIBITING THE INTERACTION OF MENIN WITH MLL PROTEINS

NºPublicación: US2018105531A1 19/04/2018

Solicitante:
KURA ONCOLOGY INC [US]
UNIV MICHIGAN REGENTS [US]

Resumen de: US2018105531A1

The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.



traducir


 

HETEROCYCLIC COMPOUNDS AND THEIR USES

NºPublicación: US2018105532A1 19/04/2018

Solicitante:
AMGEN INC [US]

Resumen de: US2018105532A1

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.



traducir


 

NEW BIOMARKER FOR OUTCOME IN AML

NºPublicación: US2018105882A1 19/04/2018

Solicitante:
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECH MEDIALE [FR]
INST JEAN PAOLI & IRENE CALMETTES [FR]
UNIV DAIX MARSEILLE
CENTRE ANTIONAL DE LA RECHERCHE SCIENT CNRS [FR]

Resumen de: US2018105882A1

The present invention relates to a method for predicting the survival time of a patient suffering from acute myeloid leukemia (AML) comprising i) determining the frequency of JAM-C expressing LSCs in a sample obtained from the patient ii) comparing the frequency determined at step i) with its predetermined reference value and iii) providing a good prognosis when the frequency determined at step i) is lower than its predetermined reference value, or 10 providing a bad prognosis when the frequency determined at step i) is higher than its predetermined reference value.



traducir


 

SIRNA OF HUMAN INTERLEUKIN 6, RECOMBINANT EXPRESSION CAR-T VECTOR, AND CONSTRUCTION METHOD AND USE THEREOF

NºPublicación: WO2018068354A1 19/04/2018

Solicitante:
SHANGHAI UNICAR THERAPY BIO MEDICINE TECH CO LTD [CN]

Resumen de: WO2018068354A1

Provided are a siRNA of the human interleukin 6, a recombinant expression CAR-T vector, and a construction method and a use thereof. The siRNA can be used in the treatment of acute B-cell lymphocytic leukemia with CAR19-T for eliminating or alleviating the symptoms of cytokine release syndrome (CRS), and can also be used for alleviating the CRS symptoms caused by treating tumours with CAR-T and even can also be used for alleviating CRS caused by other types of treatment.



traducir


 

A NOVEL INVADOPODIA-SPECIFIC MARKER OF INVASIVE CANCER STEM CELLS AND THE USE THEREOF

NºPublicación: WO2018071154A1 19/04/2018

Solicitante:
TSAI KUN CHIH
YANG PATRICK YUHMIN [US]

Resumen de: WO2018071154A1

The present invention provides an invasive cancer stem cell (iCSC) or a substantively homogeneous cell population including said iCSC based on a cell-surface biomarker specifically localizing to the invadopodia of said iCSC. The present invention further provides an invasive leukemia stem cell (iLSC) or a substantively homogeneous cell population including said iLSC based on a cell-surface biomarker specifically localizing to the invadopodia of said iLSC. The present invention also provides a method or a kit of determining a diagnosis of aggressive solid tumor or hematopoietic cancer.



traducir


 

Antibody agents specific for human CD19 and uses thereof

NºPublicación: AU2016339832A1 19/04/2018

Solicitante:
EUREKA THERAPEUTICS INC

Resumen de: AU2016339832A1

Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.



traducir


 

Methods of treating multiple myeloma and plasma cell leukemia by T cell therapy

NºPublicación: AU2016320877A1 19/04/2018

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER

Resumen de: AU2016320877A1

Disclosed herein are methods of treating multiple myeloma in a human patient in need thereof, comprising administering to the human patient a population of allogeneic cells comprising WT1-specific allogeneic T cells. Also disclosed herein are methods of treating plasma cell leukemia in a human patient in need thereof, comprising administering to the human patient a population of allogeneic cells comprising WT1-specific allogeneic T cells.



traducir


 

HODGKIN LYMPHOMA THERAPY

NºPublicación: WO2018068832A1 19/04/2018

Solicitante:
EURO CELTIQUE SA [LU]
PURDUE PHARMACEUTICAL PRODUCTS L P [US]

Resumen de: WO2018068832A1

There is provided a compound of formula I or a pharmacologically acceptable salt thereof for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said compound of formula I or a pharmacologically acceptable salt thereof: I, a combination of said compound of formula I or a pharmaceutically acceptable salt thereof with Brentuximab Vedotinand said combination for use in a method of treating Hodgkin lymphomain a patient in need thereof comprising administering to said patient an effective amount of said combination.



traducir


 

TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA

NºPublicación: WO2018071307A1 19/04/2018

Solicitante:
LILLY CO ELI [US]

Resumen de: WO2018071307A1

A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2- hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo- ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.



traducir


 

NOVEL CANNABINOID COMBINATION THERAPIES FOR MULTIPLE MYELOMA (MM)

NºPublicación: EP3307266A1 18/04/2018

Solicitante:
ONE WORLD CANNABIS LTD [IL]

Resumen de: WO2016199148A1

The present invention discloses a cytotoxic cocktail comprising: (a) a therapeutically effective amount of at least one cannabinoid selected from the group consisting of: cannabidiol (CBD) or a derivative thereof, Tetrahydrocannabinol (THC) or a derivative thereof, and any combination thereof; and (b) at least one therapeutic agent selected from the group consisting of: bortezomib (BTZ), carfilzomib (CFZ), lenalidomide (LEN), dexamethasone (DEX), melphalan (MEL) and doxorubicin (DOXO). In a core embodiment the cocktail is conferring a synergistic effect with respect to inhibition or cytotoxicity of multiple myeloma (MM) cells, relative to said at least one therapeutic agent selected from the group consisting of: BTZ, CFZ, LEN, DEX, MEL, DOXO and said CBD and THC, administered separately in a similar concentration.



traducir


 

EZH2 INHIBITORS FOR TREATING LYMPHOMA

NºPublicación: EP3307713A1 18/04/2018

Solicitante:
EPIZYME INC [US]

Resumen de: WO2016201328A1

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.



traducir


 

PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PROTEASOME INHIBITOR OR IMMUNOMODULATORY DRUG FOR THE TREATMENT OF HEMATOLOGICAL CANCER

NºPublicación: WO2018066946A1 12/04/2018

Solicitante:
CHONG KUN DANG PHARMACEUTICAL CORP [KR]

Resumen de: WO2018066946A1

The present invention relates to a pharmaceutical combination for treating a hematological cancer comprising the histone deacetylase (HDAC) inhibitor of the chemical formula 1, a proteasome inhibitor or an immunomodulatory drug and a steroidal anti-cancer agent together.The pharmaceutical combination of the present invention can be useful for treating a hematological cancer such as multiple myeloma, by reducing toxicity which is the problem of the conventional HDAC inhibitor and exhibiting an equivalent level of pharmaceutical effects due to a complex inhibitory mechanism against the cancer of the compound of chemical formula 1 and its pharmaceutically acceptable salt, the proteasome inhibitor or the immunomodulatory drug and the steroidal anti-cancer agent.



traducir


 

NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER

NºPublicación: WO2018065536A1 12/04/2018

Solicitante:
FREIE UNIV BERLIN [DE]

Resumen de: WO2018065536A1

A furazan-3-carboxylic acid derivative or pharmaceutically acceptable salt thereof for treatment of acute myeloid leukemia.



traducir


 

NT5C2 INHIBITORS USEFUL FOR THE TREATMENT OF CHEMOTHERAPY RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: WO2018067834A1 12/04/2018

Solicitante:
UNIV COLUMBIA [US]

Resumen de: WO2018067834A1

Relapse and resistance to therapy is the most significant challenge in the treatment of lymphoblastic leukemia. Mutations in NT5C2 (a cytosolic nucleotidase activated by gain of function mutations in about 20% of relapse ALL cases) characteristically are associated with early relapse and progression under therapy and confer resistance to 6-mercaptopurine chemotherapy in vitro and in vivo. Activating mutations in NT5C2 disrupt intramolecular switch-off mechanisms responsible for returning the enzyme to its resting inactive state after activation and lock the NT5C2 protein in an active state similar to that induced by allosteric activators. Based on structure, NT5C2 inhibitors were developed for specific therapies for preventing and reversing 6-MP resistance in ALL.



traducir


 

Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs

NºPublicación: AU2016326499A1 12/04/2018

Solicitante:
CELGENE CORP

Resumen de: AU2016326499A1

In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.



traducir


 

CRYSTAL FORMS OF IMMUNOMODULATORY DRUG POMALIDOMIDE AND CO-CRYSTAL WITH GENTISIC ACID

NºPublicación: US2018099944A1 12/04/2018

Solicitante:
F I S FABBRICA ITALIANA SINTETICI S P A [IT]

Resumen de: US2018099944A1

The present invention relates to novel solid crystal forms of Pomalidomide named Form B, Form M, Pomalidomide:Gentisic acid co-crystal and their preparation. Advantageously, these solid forms are used in pharmaceutical compositions for the treatment and the prevention of multiple myeloma, of inflammatory diseases, of autoimmune diseases, of immune diseases, of myelodysplastic syndrome, of myeloproliferative disorders, of anemia, of scleroderma, amyloidosis or of other diseases associated with unwanted angiogenesis.



traducir


 

ORGANIC COMPOSITIONS TO TREAT EPAS1 - RELATED DISEASES

NºPublicación: US2018100151A1 12/04/2018

Solicitante:
ARROWHEAD PHARMACEUTICALS INC [US]

Resumen de: US2018100151A1

The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.



traducir


 

PHARMACEUTICAL DOSES FOR A BROMODOMAIN AND EXTRATERMINAL PROTEIN (BET) INHIBITOR

NºPublicación: US2018098997A1 12/04/2018

Solicitante:
ONCOETHIX GMBH [CH]

Resumen de: US2018098997A1

The invention is a method for treating patients with cancer comprising administering to the patient a safe and effective dose of (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamideor a pharmaceutically acceptable salt or hydrate thereof, wherein the dose is between about 40 mg once per per day and about 120 mg once per per day. In one embodiment of the invention, the dose is about 40 mg once per per day, about 80 mg once per day or about 120 mg once per per day. In another embodiment of the invention, the dose is about 40 mg once per day. In another embodiment of the invention, the dose is about 80 mg once per day. In another embodiment of the invention, the dose is about 120 mg once per day. In another embodiment of the invention, the cancer is acute leukemia, older adult hematologic malignancy, lymphoma or multiple myeloma. In another embodiment of the invention, the lymphoma is diffuse large B-cell lymphoma.



traducir


 

THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS

NºPublicación: US2018098961A1 12/04/2018

Solicitante:
FLAVOCURE BIOTECH LLC [US]

Resumen de: US2018098961A1

An embodiment of the invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected, from among the group of Apigenin, Cannflavin. A. Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and BCL-2. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include brain, breast, colon, renal, liver, lung, pancreatic, prostate, leukemia, melanoma as well as any other cancers that overexpress the oncogenic factors inhibited by the cannabis flavonoids identified herein.



traducir


 

Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer

Nº publicación: AU2016322063A1 12/04/2018

Solicitante:
LOXO ONCOLOGY INC

Resumen de: AU2016322063A1

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver